$27,601.04 speaking Payment -- Takeda Pharmaceuticals to Dr. Gregory Evans
Oncology Physician Gregory Evans Receives Over $27,000 for Speaking Engagements from Takeda
This page provides a detailed analysis of a $27,601.04 speaking payment from Takeda Pharmaceuticals to Dr. Gregory Evans. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $27,601.04 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | Takeda Pharmaceuticals |
| Physician | Dr. Gregory Evans |
| NPI Number | 1103459172 |
| Physician Specialty | Oncology |
| Location | City, LA |
| Date of Payment | 2024-04-14 |
| Related Drug/Device | Tecfidera |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Takeda Pharmaceuticals made a $27.6K speaking payment to Gregory Evans, a Oncology specialist in City, LA. The payment was associated with Tecfidera. Gregory Evans received $27,601.04 from Takeda Pharmaceuticals for speaking engagements. The payment was for serving as faculty or a speaker, related to Tecfidera. This payment occurred on April 14, 2024, in City, LA.
Patient Guidance: What This Payment Means for You
If you are a patient, this information details payments made to healthcare providers for educational activities. It's important to discuss your treatment options and any potential conflicts of interest directly with your doctor. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
For an Oncology specialist, receiving compensation for speaking is not uncommon, but the specific drug mentioned (Tecfidera) is typically associated with other therapeutic areas, warranting further context.
Regulatory Context: Sunshine Act Requirements
Payments to physicians for speaking engagements are reportable under the Sunshine Act, requiring disclosure of the nature of the payment and the associated company and drug/device.
Related Topics
This payment is related to the following healthcare transparency topics:
- speaking-fees
- speaker-honoraria
- takeda-pharmaceuticals
- gregory-evans
- oncology
- tecfidera
- cms-open-payments
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $27.6K payment for?
This was a speaking payment of $27.6K from Takeda Pharmaceuticals to Gregory Evans, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Tecfidera. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Gregory Evans accept pharmaceutical money?
Yes, Gregory Evans received this $27.6K payment from Takeda Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Gregory Evans's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $27.6K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Oncology?
To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Gregory Evans's relationship with Takeda Pharmaceuticals?
The payment amount is substantial, indicating significant speaking activity. This $27.6K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Oncology?
The payment is specifically for 'Compensation for serving as faculty or as a speaker'.
What should patients do after learning about this payment?
If you are a patient, this information details payments made to healthcare providers for educational activities. It's important to discuss your treatment options and any potential conflicts of interest directly with your doctor.
What else should I know about this speaking payment?
Tecfidera, the associated drug/device, is often used for multiple sclerosis, not typically oncology.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.